OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
Cheol‐Kyu Park, Hyung‐Joo Oh, Young‐Chul Kim, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 8, pp. 1042-1054
Open Access | Times Cited: 19
Cheol‐Kyu Park, Hyung‐Joo Oh, Young‐Chul Kim, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 8, pp. 1042-1054
Open Access | Times Cited: 19
Showing 19 citing articles:
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
Andrea Riccardo Filippi, Jair Bar, C. Chouaid, et al.
ESMO Open (2024) Vol. 9, Iss. 6, pp. 103464-103464
Open Access | Times Cited: 11
Andrea Riccardo Filippi, Jair Bar, C. Chouaid, et al.
ESMO Open (2024) Vol. 9, Iss. 6, pp. 103464-103464
Open Access | Times Cited: 11
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
Elvis Ruznic, M. Klebermass, Barbara Zellinger, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 945-945
Open Access | Times Cited: 1
Elvis Ruznic, M. Klebermass, Barbara Zellinger, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 945-945
Open Access | Times Cited: 1
Pneumonitis Risk After Chemoradiotherapy With and Without Immunotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chong Han, Jingping Qiu, Lu Bai, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 119, Iss. 4, pp. 1179-1207
Closed Access | Times Cited: 7
Chong Han, Jingping Qiu, Lu Bai, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 119, Iss. 4, pp. 1179-1207
Closed Access | Times Cited: 7
Diagnosis and management of pneumonitis following chemoradiotherapy and immunotherapy in stage III non-small cell lung cancer
Illaa Smesseim, Onno M. Mets, Johannes M.A. Daniels, et al.
Radiotherapy and Oncology (2024) Vol. 194, pp. 110147-110147
Open Access | Times Cited: 5
Illaa Smesseim, Onno M. Mets, Johannes M.A. Daniels, et al.
Radiotherapy and Oncology (2024) Vol. 194, pp. 110147-110147
Open Access | Times Cited: 5
Real-World Insights into the Impact of Durvalumab on Stage III Unresectable Non-Small Cell Lung Cancer—A Narrative Review
Giorgio Facheris, Gianluca Cossali, Jessica Imbrescia, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 874-874
Open Access
Giorgio Facheris, Gianluca Cossali, Jessica Imbrescia, et al.
Cancers (2025) Vol. 17, Iss. 5, pp. 874-874
Open Access
Predicting severe radiation pneumonitis in patients with locally-advanced non-small cell lung cancer after thoracic radiotherapy: Development and validation of a nomogram based on the clinical, hematological, and dose-volume histogram parameters
Ying Zhang, Shi-Hong Zhou, Yujie Yan, et al.
Clinical Lung Cancer (2025)
Open Access
Ying Zhang, Shi-Hong Zhou, Yujie Yan, et al.
Clinical Lung Cancer (2025)
Open Access
Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis
Aiarpi Ezdoglian, M. Tsang-A-Sjoe, Fatemeh Khodadust, et al.
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Aiarpi Ezdoglian, M. Tsang-A-Sjoe, Fatemeh Khodadust, et al.
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 1
Open Access
Efficacy of Durvalumab Consolidation Therapy After Sequential Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer—Experience from the Daily Hospital of Clinic for Pulmonology, University Clinical Center of Serbia
Vesna Ćeriman Krstić, Natalija Samardžić, Spasoje Popević, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 892-892
Open Access
Vesna Ćeriman Krstić, Natalija Samardžić, Spasoje Popević, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 892-892
Open Access
Incidences of pneumonitis associated with the combination of radiotherapy and immune checkpoint inhibitors in lung cancer: a systematic review and meta-analysis
Jing Li, Lingli Zheng, Chaomin Liu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Jing Li, Lingli Zheng, Chaomin Liu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Franz Zehentmayr, Petra Feurstein, Elvis Ruznic, et al.
Radiotherapy and Oncology (2024) Vol. 196, pp. 110294-110294
Open Access | Times Cited: 3
Franz Zehentmayr, Petra Feurstein, Elvis Ruznic, et al.
Radiotherapy and Oncology (2024) Vol. 196, pp. 110294-110294
Open Access | Times Cited: 3
Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non–Small Cell Lung Cancer
Meghan J. Mooradian, Ling Cai, Alice Wang, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e247542-e247542
Open Access | Times Cited: 3
Meghan J. Mooradian, Ling Cai, Alice Wang, et al.
JAMA Network Open (2024) Vol. 7, Iss. 4, pp. e247542-e247542
Open Access | Times Cited: 3
Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis
Tingting Liu, Sihan Li, Silu Ding, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102246-102246
Open Access | Times Cited: 8
Tingting Liu, Sihan Li, Silu Ding, et al.
EClinicalMedicine (2023) Vol. 64, pp. 102246-102246
Open Access | Times Cited: 8
Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab After Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World Data
Jeong Yun Jang, Si Yeol Song, Young Seob Shin, et al.
Cancer Research and Treatment (2024) Vol. 56, Iss. 3, pp. 785-794
Open Access | Times Cited: 2
Jeong Yun Jang, Si Yeol Song, Young Seob Shin, et al.
Cancer Research and Treatment (2024) Vol. 56, Iss. 3, pp. 785-794
Open Access | Times Cited: 2
Efficacy of consolidation of immune checkpoint inhibitor after chemoradiation for unresectable, locally advanced PD‑L1 negative non‑small cell lung cancer: A systematic review and meta‑analysis
Sunyin Rao, Min Li, Jie Zhao, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 1
Sunyin Rao, Min Li, Jie Zhao, et al.
Oncology Letters (2024) Vol. 27, Iss. 6
Open Access | Times Cited: 1
Monocyte-Related Markers as Predictors of Immune Checkpoint Inhibitor Efficacy and Immune-Related Adverse Events: A Systematic Review and Meta-Analysis
Aiarpi Ezdoglian, M. Tsang-A-Sjoe, Fatemeh Khodadust, et al.
(2024)
Closed Access
Aiarpi Ezdoglian, M. Tsang-A-Sjoe, Fatemeh Khodadust, et al.
(2024)
Closed Access
Long-term outcomes of durvalumab after chemoradiotherapy in locally advanced non-small cell lung cancer in Russia
D. I. Yudin, К. К. Лактионов, Fedor Moiseenko, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 10, pp. 37-44
Open Access
D. I. Yudin, К. К. Лактионов, Fedor Moiseenko, et al.
Meditsinskiy sovet = Medical Council (2024), Iss. 10, pp. 37-44
Open Access
Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer
Akira Sugimoto, Hiroyasu Kaneda, Naoki Yoshimoto, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Akira Sugimoto, Hiroyasu Kaneda, Naoki Yoshimoto, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non–small‐cell lung cancer (NEJ056 )
Megumi Furuta, Hidehito Horinouchi, Isao Yokota, et al.
Cancer Science (2024)
Open Access
Megumi Furuta, Hidehito Horinouchi, Isao Yokota, et al.
Cancer Science (2024)
Open Access
Predicting severe radiation pneumonitis in patients with locally- advanced non-small cell lung cancer after thoracic radiotherapy: Development and internal validation of a nomogram based on the clinical, hematological and dose–volume histogram parameters
Ying Zhang, Yujie Yan, Shi-Hong Zhou, et al.
Research Square (Research Square) (2024)
Open Access
Ying Zhang, Yujie Yan, Shi-Hong Zhou, et al.
Research Square (Research Square) (2024)
Open Access
Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
Yuhei Kinehara, Takayuki Shiroyama, Akihiro Tamiya, et al.
JTO Clinical and Research Reports (2023) Vol. 4, Iss. 11, pp. 100586-100586
Open Access | Times Cited: 1
Yuhei Kinehara, Takayuki Shiroyama, Akihiro Tamiya, et al.
JTO Clinical and Research Reports (2023) Vol. 4, Iss. 11, pp. 100586-100586
Open Access | Times Cited: 1
